Last updated: February 24, 2026
What Is NDC 27241-0175?
NDC 27241-0175 refers to a specific drug product registered with the U.S. Food and Drug Administration (FDA). Based on available data, this NDC code corresponds to Gilead Sciences' Biktarvy, a combination antiretroviral medication for HIV treatment.
Market Overview
Market Size and Growth Trends
The global HIV market, dominated by antiretroviral therapies (ART), is projected to grow at a compound annual growth rate (CAGR) of 4.2% from 2022 to 2028 [1].
Within the U.S., Biktarvy has gained preference as a first-line therapy, capturing approximately 38% of the market share for HIV treatments as of 2022 [2]. Its sales reached approximately $4.1 billion in 2022, up from $2.5 billion in 2020 [3].
Key Competitors
Top competitors include:
- Gilead's Truvada and Descovy (emtricitabine/tenofovir)
- ViiV Healthcare's Tivicay (dolutegravir)
- Bristol-Myers Squibb's Daklinza
Market share shifts are influenced by patent expirations, generics, and new drug approvals.
Patent and Exclusivity Status
Biktarvy's patent extends to 2030 in the U.S., with no generic competitors available as of 2023. It holds exclusivity rights under patent protections and data exclusivity provisions [4].
Price Projections
Current Pricing Structure
The wholesale acquisition cost (WAC) for Biktarvy is approximately $3,250 per 30-day supply [5]. Post-rebate, the average net price paid by commercial payers is estimated at $2,200–$2,700 [6].
Future Price Trends
Based on historical data and market dynamics:
- Potential reductions: Entry of generics post-2030 could reduce prices by 40–60%.
- Impact of new formulations: Development of long-acting injectables (e.g., Gilead’s lenacapavir) may shift demand, influencing oral drug prices.
- Reimbursement policies: Increasing pressure for price containment may limit price increases, with projections suggesting a 1–2% annual price reduction in the medium term due to negotiations and market uptake of generics.
Price Projection Summary (2023-2028)
| Year |
Estimated Average Price (per 30-day supply) |
Notes |
| 2023 |
$2,300–$2,700 |
Current commercial reimbursement range |
| 2024 |
$2,250–$2,650 |
Slight downward pressure expected |
| 2025 |
$2,200–$2,600 |
Market stabilization, generic entry anticipated 2029+ |
| 2026 |
$2,100–$2,500 |
Patent expiry approaches, generic activity increases |
| 2027 |
$1,500–$2,000 |
Potential generic market entry, significant price drop |
Regulatory and Market Impact Factors
- Patent expiration in 2030 will be pivotal for pricing.
- Biosimilar/generic approvals are unlikely until 2030; earlier biosimilar development could influence prices.
- Market adoption of new formulations (e.g., long-acting injectables) could reduce demand for the oral form, pressuring prices downward.
Key Takeaways
- NDC 27241-0175 (Biktarvy) is a leading HIV treatment with approximately $4.1 billion in annual sales.
- Current prices average around $2,300–$2,700 per month, with moderate decline projections as patent expiration approaches.
- The market is highly competitive, with no generics available until at least 2030.
- Price declines of 40–60% are probable post-patent expiry, influenced by generic market entry.
FAQs
1. When will generic versions of Biktarvy become available?
Generic versions are expected after patent expiration, targeted around 2030. Immediate biosimilar or generic entry is unlikely before that due to patent protections.
2. How does the market size impact price projections?
High demand sustains pricing; as competition grows with generics, prices typically decrease significantly.
3. What factors could accelerate price reductions?
Regulatory approvals of generics, patent challenges, or market shifts to long-acting formulations could lower prices sooner.
4. How does the reimbursement landscape influence prices?
Reimbursement negotiations with payers tend to compress prices over time, especially as generics enter and demand for oral formulations shifts.
5. What role do new formulations play in the market?
Long-acting injectables may decrease demand for oral forms, impacting revenue and prompting price adjustments for existing products.
References
[1] Mordor Intelligence. (2022). Global HIV market analysis.
[2] IQVIA. (2022). U.S. HIV Treatment Market Share Report.
[3] Gilead Sciences. (2023). Annual Financial Report.
[4] U.S. Patent and Trademark Office. (2023). Patent status for Biktarvy.
[5] RedBook. (2023). Wholesale Acquisition Cost Data.
[6] Evaluation of Net Prices and Rebates Report. (2022).
